Catalyst Pharmaceuticals ... (CPRX)
Catalyst Pharmaceuticals Statistics
Share Statistics
Catalyst Pharmaceuticals has 121.45M shares outstanding. The number of shares has increased by 1.2% in one year.
| Shares Outstanding | 121.45M |
| Shares Change (YoY) | 1.2% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 82.02% |
| Shares Floating | 110.65M |
| Failed to Deliver (FTD) Shares | 10 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 6.63M, so 5.56% of the outstanding shares have been sold short.
| Short Interest | 6.63M |
| Short % of Shares Out | 5.56% |
| Short % of Float | 6.29% |
| Short Ratio (days to cover) | 5.54 |
Valuation Ratios
The PE ratio is 15.08 and the forward PE ratio is 11.62. Catalyst Pharmaceuticals's PEG ratio is 0.14.
| PE Ratio | 15.08 |
| Forward PE | 11.62 |
| PS Ratio | 5.03 |
| Forward PS | 3.5 |
| PB Ratio | 3.4 |
| P/FCF Ratio | 17.24 |
| PEG Ratio | 0.14 |
Enterprise Valuation
Catalyst Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.65B.
| EV / Earnings | 10.08 |
| EV / Sales | 3.36 |
| EV / EBITDA | 8.47 |
| EV / EBIT | 8.47 |
| EV / FCF | 11.53 |
Financial Position
The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.
| Current Ratio | 5.17 |
| Quick Ratio | 5.01 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.38 |
| Cash Flow / Debt | 51.54 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.23% and return on capital (ROIC) is 20.24%.
| Return on Equity (ROE) | 0.23% |
| Return on Assets (ROA) | 0.19% |
| Return on Capital (ROIC) | 20.24% |
| Revenue Per Employee | $2,716,762.43 |
| Profits Per Employee | $905,464.09 |
| Employee Count | 181 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 3.52 |
Taxes
| Income Tax | 52.37M |
| Effective Tax Rate | 0.24 |
Stock Price Statistics
The stock price has increased by 52.2% in the last 52 weeks. The beta is 0.84, so Catalyst Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | 52.2% |
| 50-Day Moving Average | 22.64 |
| 200-Day Moving Average | 20.43 |
| Relative Strength Index (RSI) | 62.78 |
| Average Volume (20 Days) | 1.35M |
Income Statement
In the last 12 months, Catalyst Pharmaceuticals had revenue of 491.73M and earned 163.89M in profits. Earnings per share was 1.38.
| Revenue | 491.73M |
| Gross Profit | 422.89M |
| Operating Income | 195.12M |
| Net Income | 163.89M |
| EBITDA | 195.12M |
| EBIT | 195.12M |
| Earnings Per Share (EPS) | 1.38 |
Balance Sheet
The company has 517.55M in cash and 2.79M in debt, giving a net cash position of 514.77M.
| Cash & Cash Equivalents | 517.55M |
| Total Debt | 2.79M |
| Net Cash | 514.77M |
| Retained Earnings | 285.16M |
| Total Assets | 851.41M |
| Working Capital | 502.93M |
Cash Flow
In the last 12 months, operating cash flow was 143.6M and capital expenditures -231K, giving a free cash flow of 143.37M.
| Operating Cash Flow | 143.6M |
| Capital Expenditures | -231K |
| Free Cash Flow | 143.37M |
| FCF Per Share | 1.21 |
Margins
Gross margin is 86%, with operating and profit margins of 39.68% and 33.33%.
| Gross Margin | 86% |
| Operating Margin | 39.68% |
| Pretax Margin | 43.98% |
| Profit Margin | 33.33% |
| EBITDA Margin | 39.68% |
| EBIT Margin | 39.68% |
| FCF Margin | 29.16% |
Dividends & Yields
CPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.69% |
| FCF Yield | 4.87% |
Analyst Forecast
The average price target for CPRX is $32, which is 31.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 31.9% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 17.2 |
| Piotroski F-Score | 7 |